Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.52 ▼ -0.02
(-2.92%)
MKT CAP: $1.4M • VOL: 46.0K
52W L $0 52W H $16
ROARABLE / RQD
E • 29/100
PIOTROSKI
3 / 9
SCNI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.3M | $658.0K | $0 |
| YoY Revenue Growth % | +99.2% | — | — |
| Gross Profit | -$2.7M | -$580.0K | — |
| Gross Margin % | -50.0% | -50.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.5M | -$8.6M | -$9.7M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$8.3M | $4.8M | -$6.5M |
| EBITDA (Normalized) | -$7.5M | -$8.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.0M | -$6.3M | -$9.4M |
| Capital Expenditures (CapEx) | $24.0K | $12.0K | — |
| Free Cash Flow (FCF) | -$6.1M | -$6.3M | -$9.4M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.7M | $2.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.1M | $10.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SCNI.